Elephas Biosciences Corporation, developer of an innovative live tissue platform for immunotherapy response prediction, announced on Tuesday that it has entered into an international partnership with life sciences company Invitrocue Pte Ltd.

Under the agreement, Invitrocue, a personalised oncology company specialising in 3D cell-based cancer models (organoids) and comprehensive genomic profiling (CGP), will serve as Elephas' commercial partner for the elive platform in Singapore and Malaysia.

Invitrocue's flagship Singapore laboratory, Angsana Molecular & Diagnostics Laboratory, provides the foundation to extend access across Southeast Asia.

This partnership brings together three complementary approaches: Invitrocue's Onco-PDO functional drug testing service, its suite of CGP tests, and Elephas' elive platform for ex vivo immunotherapy response insight. Together, these technologies provide researchers and clinicians with a more complete personalised oncology testing pathway, integrating functional drug screening, genomic profiling, and immunotherapy response prediction, Elephas said.